MedPath

Pillar Biosciences and Hamilton Partner to Automate NGS Testing with Advanced Liquid Handling Systems

• Pillar Biosciences and Hamilton Company have formed a strategic partnership to develop automated NGS testing solutions, initially focusing on the oncoReveal Essential MPN panel.

• The collaboration aims to address key barriers in NGS testing adoption by combining Pillar's NGS products with Hamilton's Microlab STAR Liquid Handling Systems to reduce time, costs, and workflow complexity.

• The partnership will cover markets across North America, Central America, South America, New Zealand, and APAC Countries, expanding access to efficient NGS testing solutions.

In a significant move to advance precision medicine capabilities, Pillar Biosciences, Inc., a leader in Decision Medicine™, has established a strategic partnership with Hamilton Company to automate next-generation sequencing (NGS) testing processes. The collaboration, announced today, focuses on developing automation scripts and technical solutions for Pillar's research-use-only (RUO) NGS panels.
The partnership's initial phase will center on automating Pillar's oncoReveal® Essential MPN panel using Hamilton's sophisticated Microlab® STAR™ Liquid Handling Systems. This integration aims to streamline complex NGS testing workflows and enhance laboratory efficiency.

Addressing Market Challenges

"Time, workflow complexity and overall testing costs are barriers for the broader adoption of localized NGS testing solutions," explained Dan Harma, CCO of Pillar Biosciences. The collaboration seeks to overcome these obstacles by combining Pillar's streamlined NGS products with Hamilton's automated liquid handling expertise.
The partnership promises to deliver several key benefits to laboratories and healthcare providers:
  • Faster turnaround times for tumor profiling results
  • Reduced labor costs through automation
  • Enhanced testing efficiency and reliability
  • Broader access to NGS testing capabilities

Technology Integration and Market Impact

Michael Mouradian, Vice President of Scientific Strategy and Market Development at Hamilton, emphasized the strategic value of the partnership: "By combining Pillar's cutting-edge NGS solutions with Hamilton's proven automation technology and global reach, we are providing customers with a more accessible and efficient solution to accelerate NGS testing."
The automation solutions will leverage Pillar's proprietary technologies, including SLIMamp® and PiVAT®, which are designed to localize testing processes and reduce diagnostic costs. This integration with Hamilton's automated systems aims to create a more streamlined and accessible NGS testing ecosystem.

Geographic Expansion

The application development and co-marketing agreement encompasses a broad geographic scope, including:
  • North America
  • Central America
  • South America
  • New Zealand
  • All APAC Countries
This extensive coverage ensures that laboratories across these regions will have access to advanced NGS automation solutions, potentially transforming how genetic testing is conducted in these markets.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

LabConnect and Australian Clinical Labs Form Strategic Alliance to Expand Clinical Trial Services in Asia-Pacific

LabConnect and Australian Clinical Labs' Specialised Trials have established a multi-year partnership to enhance clinical trial support services across Australia and the Asia-Pacific region.
The collaboration leverages ACL's extensive laboratory network and LabConnect's global expertise to support pharmaceutical trials from Phase 1 to Phase 4, strengthening their position in an $8 billion market.

MGI Tech and Oncoclinicas&Co Partner to Advance Genomic Cancer Diagnostics in Brazil

Strategic partnership between MGI Tech and Oncoclinicas&Co aims to expand access to advanced genomic testing and enhance oncology diagnostic capabilities across Brazil.
Cancer mortality has surpassed cardiovascular deaths in 727 Brazilian cities, highlighting the urgent need for improved early detection and treatment monitoring solutions.

Flatiron Health and Exact Sciences Launch Major Study to Validate Novel Cancer Recurrence Test

Flatiron Health and Exact Sciences have initiated a groundbreaking partnership to evaluate Oncodetect, a molecular residual disease test, across multiple solid tumor types.
The prospective clinical study will enroll 1,350 patients from community settings, focusing on historically underrepresented populations in clinical trials.

Corsair Pharma Adopts InstantGMP's Digital Platform to Advance PAH Treatment Development

Corsair Pharma has partnered with InstantGMP to implement digital quality and document management systems as they prepare for Phase 1 trials of their novel treprostinil prodrug patch for PAH treatment.
The collaboration introduces advanced quality assurance measures and streamlined document management, ensuring compliance with US, UK, and European regulations while reducing operational errors.

Catalent and Galapagos Partner to Advance Decentralized CAR-T Manufacturing for NHL Treatment

Catalent and Galapagos NV have formed a strategic collaboration to support decentralized manufacturing of GLPG5101, an investigational CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma.
The partnership leverages Catalent's Princeton facility to deliver fresh CAR-T cells with a median vein-to-vein time of seven days, eliminating the need for cryopreservation and bridging therapy.

Biofidelity and CellCarta Partner to Expand Genomic Testing in Global Lung Cancer Clinical Trials

Biofidelity and CellCarta have formed a strategic partnership to deploy Biofidelity's Aspyre® Lung assay in global clinical trials, enhancing precision medicine solutions.
Aspyre Lung simplifies NSCLC biomarker detection by analyzing DNA and RNA from tissue and blood samples using a streamlined four-step workflow.

Palatin Technologies Advances PL8177 for Ulcerative Colitis and Bremelanotide for Obesity

Palatin Technologies has completed enrollment in its Phase 2 study of oral PL8177 for ulcerative colitis, with topline data expected in Q1 2025.
Preclinical data suggests PL8177 may resolve damaging inflammation in the colon, offering a potential alternative to immunosuppressants.

Harbinger Health Partners with Memorial Sloan Kettering to Accelerate Early Cancer Detection Test Validation

Harbinger Health collaborates with Memorial Sloan Kettering to expedite clinical validation of its AI-supported blood test for early-stage cancer detection.
The test, based on methylation pattern analysis, aims to detect the 20 most prevalent cancer types before metastasis, ideally at stage I.

NMPA Approves First NGS-Based Companion Diagnostic for Lung Cancer with Sunvozertinib

The NMPA has approved the first co-developed NGS-based companion diagnostic (CDx) for lung cancer in China, LungCure CDx, developed by Burning Rock and Dizal.
LungCure CDx is designed to identify EGFR exon 20 insertion mutations in NSCLC patients, guiding the use of Dizal's targeted therapy, sunvozertinib.

Agilent Launches Biopharma CDx Services Lab to Advance Precision Medicine

Agilent Technologies has launched its Biopharma CDx Services Lab (BCSL) in Carpinteria, California, after receiving necessary certifications.
The BCSL will support drug development from early clinical studies through regulatory approval, offering efficient companion diagnostic development.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy